

# TING-JEN RACHEL CHENG, PH.D. (鄭婷仁)

128 Sec 2 Academia Road, Nankang  
Taipei 115, Taiwan

Office: +886-2-27899930 x 321  
Email: [tingjenc@gate.sinica.edu.tw](mailto:tingjenc@gate.sinica.edu.tw)

---

## RESEARCH INTEREST

---

My interest is in the area of drug discovery and development, specifically, (1) Target discovery and validation of diseases, especially for antibiotics resistance, (2) Target-based or cell-based assay development for drug screening, (3) identification of molecular mechanisms of drug actions.

---

## SUMMARY OF QUALIFICATIONS

---

A dedicated biologist with a proven track record of research excellence and significant accomplishments. Scientific expertise:

- ◆ *Drug Discovery* — develop and optimize both target-based and cell-based assays in a high throughput format for drug screening.
- ◆ *Molecular Biology* — proficient in different cloning strategies, random mutagenesis, site-directed mutagenesis, and various expression systems to produce functional proteins for in vitro analysis, and design different reporter system for cell-based assay.
- ◆ *Cell Biology* — standardize the operations of mammalian cell culture facility, develop protein localization analysis, and analyze the transcriptional regulations of genes.
- ◆ *Protein Chemistry* — develop strategies of protein purification, analyze protein expression profiles, and design protein phosphorylation analysis.
- ◆ *Computational analysis* — working knowledge of chemical and biological databases, chemoinformatic analysis of interactions between small molecules and specific targets.

---

## EDUCATION

---

<i>Ph.D., Life Sciences</i> , National Tsing Hua University, Hsinchu, Taiwan	1999
<i>B. Eng., Chemical Engineering</i> , National Tsing Hua University, Hsinchu, Taiwan	1993

---

## PROFESSIONAL EXPERIENCES

---

<i>Postdoctoral Fellow</i>	2000-present
----------------------------	--------------

Keck Graduate Institute of Applied Life Sciences, Claremont, California, United States

- Developed target-based assays in a high throughput format to facilitate anti-cancer drug screening.
- Developed a model system for screening of novel HIV protease inhibitor(s).
- Identified novel HIV protease inhibitors by using high-throughput screening of chemical libraries.
- Established drug resistance profiles of HIV protease variants using target-based and cell-based systems.
- Employed current molecular biology techniques to obtain functional recombinant enzymes for in vitro analysis.
- Participated in developing and optimizing an algorithm for integration of HIV-antiviral drug actions and sequence information of HIV virus strains.

---

**PROFESSIONAL EXPERIENCES (CONT'D)**


---

*Project Manager* 1999-2000

Maxigen Biotech Inc., Taipei, Taiwan

- Successfully conducted technology transfer of collagen extraction and purification for wound healing products.
- Coordinated research resources and facilities.

*Research Associate* 1992-1999

Department of Life Sciences, National Tsing Hua University, Hsinchu, Taiwan

- Investigated signaling pathways leading to apoptosis, reorganization of intermediate filaments, and differential expression of specific genes in drug-treated cells.
- Discovered a new kinase, mitogen-activated protein kinase-activated protein kinase-2 (MAPKAPK-2), and protein phosphatase 2A are involved in the pathways leading to reorganization of cytoskeleton.
- Analyzed co-localization of protein phosphatase 2A and intermediate filaments. Investigated compartmentalization of heat shock proteins in the cells experienced heat treatment.
- Designed and constructed protein variants for functional studies.
- Performed protein phosphorylation analysis. Determine protein modification site(s) by peptide mapping and manual Edman degradation.
- Supervised the daily operations of the laboratory of Professor Yiu-Kay Lai in the Department of Life Sciences, National Tsing Hua University, Hsinchu, Taiwan.

*Summer Intern* 1995

Department of Medicinal Chemistry, Univ. of North Carolina, North Carolina, United States

- Conducted anti-cancer drug screening by DNA topoisomerase II activity assay.
- Analyzed cytotoxicity of anti-cancer drug candidates.

---

**PROFESSIONAL AFFILIATION**


---

American Society of Microbiology (2003-present)

---

**CERTIFICATE**


---

Technical Writing (Clemson University, 2004)

---

**PUBLICATIONS**


---

1. Cheng, T.-J.\*, Goodsell, D., and Kan, C.-C. Identification of sanguinarine as a novel HIV protease inhibitor. *Letters in Drug Design & Discovery*. In press (2005)
2. Cheng, T.-J.\*, Brik, A., Wong, C.-H., and Kan, C.-C. Model system for high-throughput screening of the human immunodeficiency virus (HIV) protease inhibitors in *Escherichia coli*. *Antimicrob. Agents Chemother.* 48,2437-2447 (2004).
3. Cheng, T.-J.\*, Tseng, Y.-F., Chang, W.-M., Chang, M.D.-T., and Lai, Y.-K. Retaining of the assembly capability of vimentin phosphorylated by mitogen-activated protein kinase-activated protein kinase-2. *J. Cell. Biochem.* 89,589-602 (2003).

4. Cheng, T.-J.\*, Rey, P.G., Poon, T., and Kan, C.-C. Kinetic studies of human tyrosyl-DNA phosphodiesterase, an enzyme in the topoisomerase I DNA repair pathway. *Eur. J. Biochem.* 269,3697-704 (2002).
5. Cheng, T.-J.\*, Lin, Y.-L., Chiang, A.-S., and Lai, Y.-K. Association of protein phosphatase 2A and its substrate vimentin intermediate filaments in 9L rat brain tumor cells. *J. Cell. Biochem.* 79,126-138 (2000).
6. Hung, J.-J., Cheng, T.-J.\*, Lai, Y.-K., Chang, M.D.-T. Differential activation of p38 mitogen-activated protein kinase and extracellular signal-regulated protein kinase confers cadmium-induced HSP70 expression in 9L rat brain tumor cells. *J. Biol. Chem.* 273:31924-31931 (1998).
7. Cheng, T.-J.\*, and Lai, Y.-K. Identification of mitogen-activated protein kinase-activated protein kinase-2 as a vimentin kinase activated by okadaic acid in 9L rat brain tumor cells. *J. Cell. Biochem.* 71,169-181 (1998).
8. Hung, J.-J., Cheng, T.-J.\*, Chang, M.D.-T., Chen, K.-D., Huang, H.-L., and Lai, Y.-K. Involvement of heat shock elements and basal transcription elements in the differential induction of the 70-kDa heat shock protein and its cognate by cadmium chloride in 9L rat brain tumor cells. *J. Cell. Biochem.* 71,21-35 (1998).
9. Wang, T.-T., Chiang, A.-S., Chu, J.-J., Cheng, T.-J.\*, Chen, T.-M., and Lai, Y.-K. Concomitant alterations in distribution of 70 kDa heat shock proteins, cytoskeleton, and organelles in heat shocked 9L cells. *Intl. J. Biochem. Cell Biol.* 30,745-756 (1998).
10. Cheng, T.-J.\*, Chen, T.-M., Chen, C.-H., and Lai, Y.-K. Induction of stress response and differential expression of 70 kDa stress proteins by sodium fluoride in HeLa and rat brain tumor 9L cells. *J. Cell. Biochem.* 69,221-231 (1998).
11. Perng, M.-D., Cheng, T.-J.\*, Chen, C.-M., and Lai, Y.-K. Induction of aggregation and augmentation of protein kinase-mediated phosphorylation of purified vimentin intermediate filaments by Withangulatin A. *Mol. Pharmacol.* 46,612-617 (1994).
12. Cheng, T.-J.\*, and Lai, Y.-K. Transient increase in vimentin phosphorylation and vimentin-HSC70 association in 9L rat brain tumor cells experiencing heat-shock. *J. Cell. Biochem.* 54:100-109 (1994).

---

## PATENTS

---

U.S. Patent 6,787,327

September 7, 2004

For: Human tyrosine-DNA phosphodiesterase variant polypeptides and method of use thereof

U.S. Provisional Patent Application

Filed on March 15, 2004

For: A model system for high-throughput screening of novel human immunodeficiency virus (HIV) protease inhibitors in *Escherichia coli*

U.S. Provisional Patent Application

Filed on May, 2003

For: Model System for In-vivo and In-vitro screening of protease inhibitors